This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Bevacizumab Effect on Blood Velocity

This study has been completed.
Information provided by:
Optical Imaging, Ltd. Identifier:
First received: February 16, 2011
Last updated: NA
Last verified: February 2011
History: No changes posted
Retinal blood flow velocity is affected by Bevacizump intravitreal injection. This effect is correlated to treatment success.

Choroidal Neovascularization

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The Effect of Intravitreal Bevacizumab (Avastin) Injection on Retinal Blood-Flow Velocity in Patients With Choroidal Neovascularization

Resource links provided by NLM:

Further study details as provided by Optical Imaging, Ltd.:

Primary Outcome Measures:
  • Blood flow velocity change [ Time Frame: 1 day following injection ]

Enrollment: 12
Study Start Date: January 2008
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Detailed Description:
The purpose of the study was to carry out a pilot study on the short-term effect of intravitreal Bevacizumab (Avastin) injection on retinal blood-flow velocity and test whether the short-term haemodynamic changes could predict the longer term clinical result of the treatment.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with choroidal neovascularization (CNV)

Inclusion Criteria:

  • Patients with CNV receiving Bevacizumab intravitreal injection

Exclusion Criteria:

  • Candidates in whom the retina could not be seen clearly because of media opacity or a poorly dilating pupil
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01298440

Tel aviv sourasky medical center
Tel aviv, Israel, 64239
Sponsors and Collaborators
Optical Imaging, Ltd.
Principal Investigator: Adiel Barak, MD Tel aviv university Sackler school of medicine
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Optical Imaging, Ltd Identifier: NCT01298440     History of Changes
Other Study ID Numbers: AvastinRFI
Study First Received: February 16, 2011
Last Updated: February 16, 2011

Additional relevant MeSH terms:
Neovascularization, Pathologic
Choroidal Neovascularization
Pathologic Processes
Choroid Diseases
Uveal Diseases
Eye Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on September 21, 2017